Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : Rare save search
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -10.79%
H: 0.0%
C: -3.75%
gtx-102 positive treatment
Ultragenyx Announces Data Demonstrating Treatment with UX111
Published: 2024-02-06 (Crawled : 14:00) - biospace.com/
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.67%
H: 2.0%
C: 1.84%
ux111 treatment
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.67%
H: 2.0%
C: 1.84%
ux111 treatment results
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
Published: 2024-02-05 (Crawled : 21:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.67%
H: 2.0%
C: 1.84%
gtx-102 treatment designation prime
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2024-01-25 (Crawled : 21:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.55%
H: 1.01%
C: -1.16%
ux701 disease treatment therapy study
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Published: 2023-09-25 (Crawled : 21:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.46%
H: 4.26%
C: 1.55%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
evkeeza treatment hypercholesterolemia canada
Addressing the Fragile: 2023 Global Osteogenesis Imperfecta Treatment Market's Growth Driven by Research and Collaboration
Published: 2023-09-04 (Crawled : 16:00) - prnewswire.com
MREO | $2.64 -0.38% -0.38% 910K
|
Health Technology
| Email alert
Add to watchlist
VTRS | $11.25 1.17% 1.16% 4.7M
|
Health Technology
| Email alert
Add to watchlist
KIDS | $30.35 3.02% 2.93% 140K
|
Health Technology
| Email alert
Add to watchlist
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
| Email alert
Add to watchlist
treatment research global collaboration growth
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2023-07-31 (Crawled : 16:00) - biospace.com/
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.81%
H: 1.93%
C: -0.78%
ux701 disease treatment trial therapy
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Published: 2023-07-06 (Crawled : 12:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -1.06%
H: 0.24%
C: -0.91%
MREO | $2.64 -0.38% -0.38% 910K
|
Health Technology
|
| O: -2.34%
H: 2.0%
C: -1.6%
ux143 treatment program
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
Published: 2022-04-20 (Crawled : 12:20) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.15%
H: 1.14%
C: 0.06%
MREO | $2.64 -0.38% -0.38% 910K
|
Health Technology
|
| O: 3.09%
H: 0.0%
C: -9.78%
ux143 treatment phase 2
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
Published: 2021-12-01 (Crawled : 15:00) - biospace.com/
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.25%
H: 3.1%
C: 0.98%
treatment disease phase 1 therapy
Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency
Published: 2021-10-26 (Crawled : 14:15) - biospace.com/
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: 0.0%
MREO | $2.64 -0.38% -0.38% 910K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
treatment biopharma orphan drug drug designation alvelestat
Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2021-10-18 (Crawled : 17:00) - biospace.com/
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -1.4%
H: 0.27%
C: -1.09%
disease treatment gene therapy therapy trial
GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.07%
H: 0.34%
C: -6.71%
treatment fda phase 1 clinical hold syndros
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy
Published: 2021-09-09 (Crawled : 08:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.58%
H: 2.56%
C: -0.46%
media treatment approval
MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults
Published: 2021-09-07 (Crawled : 12:15) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 1.8%
H: 1.99%
C: -0.35%
canada approval media treatment injection approval
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and ChildrenDojolvi is the only approved therapy for this rare, life-threatening metabolic disorder
Published: 2021-08-23 (Crawled : 13:00) - biospace.com/
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 4.68%
H: 4.22%
C: 4.04%
treatment brazil therapy metabolic children approval rare
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
Published: 2021-08-23 (Crawled : 13:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 4.68%
H: 4.22%
C: 4.04%
treatment brazil children approval
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain
Published: 2021-07-13 (Crawled : 08:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.16%
H: 2.26%
C: -4.01%
media treatment approval
GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome
Published: 2021-06-10 (Crawled : 13:00) - globenewswire.com
RARE F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.2%
H: 8.89%
C: 5.07%
treatment approval syndros
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.